The news: The Trump administration may revive a proposal from the president’s first term that would more closely align US drug prices to lower amounts paid by other developed countries, according to a Reuters report.

The proposition is a “mid-level priority” for the administration. An initial pilot could entail testing drug pricing proposals in Medicare and Medicaid, per Reuters.

Zooming out: Trump’s “most-favored nation” executive order in 2020 called for a pricing model in which the US wouldn’t pay more than the lowest price charged in other similar countries for the 50 highest-expenditure Medicare Part B drugs and biologicals. The government at the time projected that the policy would save taxpayers more than $85 billion over seven years.